DMT Adherence While Pregnant Is Tied to Lower Medical Costs
Women diagnosed with multiple sclerosis (MS) and being treated with disease-modifying therapies (DMTs) who become pregnant often discontinue those agents, as none are approved for use during pregnancy. But a recent study by AllianceRx Walgreens Prime, in conjunction with parent company Walgreens, demonstrates that when these women remain adherent to DMTs, this may reduce their nonmaternity inpatient and outpatient costs.
The findings were presented at the virtual Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2021, which was held at the end of February.
Study Finds Fertility Program Prevents Medication Waste, Loss, Missed DosesREAD MORE
New FDA Approvals: FDA Expands Patient Population of Takeda’s HyQviaREAD MORE